
Brand-name and generic pharmaceutical groups are recommending clarifications to the FDA guidance on when to submit an abbreviated new drug application or a 505(b)(2) new drug application. hubs.la/Q04FvF6p0

The Regulatory Affairs Professionals Society (RAPS) is an international membership organization of regulatory professionals in the healthcare products sector.

Brand-name and generic pharmaceutical groups are recommending clarifications to the FDA guidance on when to submit an abbreviated new drug application or a 505(b)(2) new drug application. hubs.la/Q04FvF6p0

The FDA recently issued warning letters to three manufacturers of active pharmaceutical ingredients based in China. hubs.ly/Q04FlxSc0

The FDA is requesting feedback on possible solutions that would help sponsors more effectively submit patient-level real-world data and real-world evidence for drug and biological product applications. hubs.la/Q04FcP770

Acting US FDA Commissioner Kyle Diamantas said there is significant public interest in its recently announced Expedited Investigational New Drug pilot at the Friends of Cancer Research annual meeting on Tuesday. hubs.la/Q04F5x3y0

The FDA has issued draft guidance to assist sponsors in developing early-phase first-in-human studies for investigational drugs and biologics aimed at treating solid tumors as part of Operation TrialBlazer. hubs.la/Q04F4ZMt0

FDA on Monday finalized guidance to assist manufacturers in validating in vitro diagnostic devices that test for emerging pathogens during public health emergencies. hubs.la/Q04DSBsC0

A FDA official stated that the midterm congressional election results will not likely impact the reauthorization of the agency’s user fee agreements, which have been negotiated for FY 2028-2032. hubs.la/Q04Dzg_L0

As artificial intelligence (AI) permeates the regulatory world, experts said it won't take over regulatory professionals' jobs but will instead help them work more efficiently and dedicate more time on human interactions. hubs.la/Q04DqZ6G0

Sarah Yim, director of the FDA Office of Therapeutic Biologics and Biosimilars in the Office of New Drugs, emphasized that the agency is actively working to help sponsors reduce their reliance on clinical efficacy studies. hubs.la/Q04Dq0Pl0

A top US FDA enforcement official announced that the agency conducted more unannounced drug inspections in India and China in FY 2026 compared to the previous year. hubs.la/Q04DfkBZ0

More than 500 comments have been submitted in response to the FDA discussion paper on generative AI (genAI)-enabled medical devices, and stakeholders have offered the agency a wide variety of advice on the best way to regulate these technologies. hubs.la/Q04DfhV70

Patients who reviewed and signed a patient agreement form (PAF) for mifepristone and misoprostol under the FDA risk evaluation and mitigation strategy program were equally knowledgeable about medication abortion. hubs.la/Q04D4Nc_0

FDA issued revised draft guidance on Thursday aimed at assisting sponsors of drug-device combination products in designing and developing essential drug delivery device performance characteristics for their products. hubs.la/Q04C-kj80

The Department of Health and Human Services has announced that it will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound six unapproved peptide bulk drug substances. hubs.la/Q04CSkrv0

FDA on Tuesday issued draft guidance on submitting investigational device exemption applications electronically using the electronic Submission Template and Resource template. Joanne Eglovitch reports for Regulatory Focus: hubs.la/Q04CKYq10

An expert and officials from FDA offered tips for de novo classification requests and reviewed some of the changes related to de novos being proposed under the Medical Device User Fee Amendments (MDUFA VI) program at The MedTech Conference last week. hubs.la/Q04CzrDS0